Diagens Plans to Broaden Business Scope to AI, Big Data and Telecom Services; Seeks Shareholder Approval on 23 July 2026

Hangzhou Diagens Biotechnology Co., Ltd. (Diagens, 02526) has announced a proposal to expand its business scope significantly beyond its existing biochemical R&D and medical-device activities. The Board is seeking shareholder approval at an extraordinary general meeting (EGM) scheduled for 23 July 2026.

Key proposed additions 1. Digital & AI capabilities • Software development and computer system integration • Big-data services, data processing and storage support, internet data services • Development of basic and applied artificial-intelligence software; sales of AI hardware; AI industry application systems integration

2. ICT product sales and support • Retail and wholesale of computer software, hardware and auxiliary equipment • Sales of electronic products, communication equipment, instruments and meters • Operation and maintenance services of information systems

3. Telecom licences (new “Licensed items”) • Class II value-added telecommunications services • Internet information services

4. Existing core businesses retained • R&D and production of biochemical products • Manufacturing and sales of Class I–III medical devices • Production and sales of non-hazardous chemical and specialty chemical products • Import and export of goods and technology

Procedural timeline • 8 July 2026: Dispatch of EGM circular and formal notice to shareholders • 23 July 2026: EGM vote on special resolution covering the revised business scope and corresponding amendments to the Articles of Association • Post-approval: Filing of changes with market supervision and administration authorities before the updated scope becomes effective

Board composition (as of 7 July 2026) Executive Directors: Dr. Song Ning (Chairman, GM), Mr. Weng Chih-Hsin Non-executive Directors: Dr. Xu Chen, Dr. Wu Lingqian, Mr. Yang Zehao Independent Non-executive Directors: Mr. Cha Yang, Ms. Zhang Jing, Mr. Wang Kaifeng

Implications The proposed shift marks Diagens’ strategic intent to diversify into high-growth digital technology arenas—artificial intelligence, big data and telecommunications—alongside its established biotechnology and medical-device operations. Shareholder endorsement and regulatory clearance remain prerequisites for implementation.